Clinical trial

A Randomized, Examiner Blind, Crossover, in Situ Erosion Study To Investigate The Efficacy Of An Experimental Dentifrice In Remineralization Of Softened Enamel Compared To Placebo and Reference Dentifrices

Name
300057
Description
The purpose of this study is to investigate the ability of an experimental dentifrice containing 1150 parts per million (ppm) fluoride to remineralize acid-softened dental enamel and help prevent further demineralization compared to a 0 ppm fluoride placebo dentifrice and a marketed, fluoride-containing dentifrice (Reference Dentifrice).
Trial arms
Trial start
2024-02-26
Estimated PCD
2024-05-02
Trial end
2024-05-02
Status
Active (not recruiting)
Treatment
Experimental Dentifrice
Dentifrice containing 1150 ppm fluoride and 5% KNO3.
Arms:
Experimental Dentifrice
Placebo Control Dentifrice
Dentifrice containing 0 ppm fluoride and 5% KNO3.
Arms:
Placebo Control Dentifrice
Reference Dentifrice
Dentifrice containing 1100 ppm fluoride as SnF2.
Arms:
Reference Dentifrice
Other names:
Crest Pro-Health Densify Daily Protection
Size
33
Primary endpoint
Percent Surface Microhardness Recovery (%SMHR) at 4 Hours (Experimental Dentifrice Versus (vs.) Placebo Dentifrice)
At 4 hours of intra-oral exposure
Eligibility criteria
Inclusion Criteria: * Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed. * Participant is of either sex and any gender who, at the time of screening, is between the ages of 18-65 years, inclusive. * Participant is willing and able to comply with scheduled visits, and other study procedures and restrictions. * Participant is in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements. * Participant with generally good oral health that fulfil all of the following: 1. Having an unstimulated salivary flow rate of at least 0.2 milliliter per minute (mL/minute) and a stimulated salivary flow rate of at least 0.8 mL/minute. 2. Having a maxillary dental arch suitable for the retention of the palatal appliance. 3. Having no lesions of the oral cavity that could interfere with the study evaluations. Exclusion Criteria: * Participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a Haleon employee directly involved in the conduct of the study or a member of their immediate family (employees of the study site and associated academic institutes who are not directly involved in the conduct of the study are eligible to be considered as participants.) * Participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation. * Participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study. * Participant who is pregnant (self-reported) or intending to become pregnant over the duration of the study or who is breastfeeding. * Participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. * A participant who, in the opinion of the investigator or medically qualified designee, can't comply with study requirements or who should not participate in the study for other reasons. * Participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol. * Participant taking medication that may interfere significantly with the saliva flow in the judgment of the investigator. Should new medications that may interfere with the saliva flow be added, a second salivary flow test will be performed. * Participant with any condition that would impact on their safety or wellbeing or affect their ability to understand and follow study procedures and requirements. * Participant with any sign of grossly carious lesions (active), moderate or severe periodontal conditions, or severe tooth wear. Participant presenting at screening with minor caries may continue in the study if their carious lesions are repaired prior to the first treatment visit of the study. * Participant who wears an oral piercing or oral appliance or orthodontia (besides participants wearing permanent lower retainers, which are eligible). * Participant who has previously been enrolled in this study.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['INVESTIGATOR']}}, 'enrollmentInfo': {'count': 33, 'type': 'ACTUAL'}}
Updated at
2024-03-15

1 organization

3 products

1 indication

Organization
Haleon
Indication
Dental Erosion
Product
Dentifrice